NASDAQ$BMRN
BioMarin Pharmaceutical Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
BioMarin's Q4 2019 financial results were announced, showcasing significant revenue growth driven by key products and strategic advancements in its pipeline.
BioMarin announced a 29% increase in total revenues for Q4 2019, reaching $454.4 million compared to $353.2 million in Q4 2018. The growth was primarily driven by increased net product revenues, particularly from Palynziq, Vimizim, Naglazyme, and Brineura. The company also reported a GAAP net income of $15.0 million for the quarter, a significant improvement from the net loss of $3.7 million in the same period of the previous year.
- Total revenues for Q4 2019 increased by 29% to $454.4 million.
- GAAP Net Income improved to $15.0 million from a loss of $3.7 million in Q4 2018.
- Palynziq revenues increased significantly due to maintenance dosing and new patients initiating therapy.
- Advancements in the pipeline include FDA and EMA acceptance of marketing submissions for Valoctocogene Roxaparvovec.
Headline financials
Revenue & EPS history
BioMarin · Revenue · Quarterly
$454M
Revenue by segment
BioMarin · $431M total across 6 segments · Q4 2019
- VIMIZIM$132M+16.1%30.7%
- KUVAN$123M+9.3%28.5%
- NAGLAZYME$94.8M+23.6%22.0%
- PALYNZIQ$31.7M+291.4%7.4%
- BRINEURA$25.2M+106.6%5.9%
- ALDURAZYME$23.9M+37.4%5.6%
Forward guidance
BioMarin anticipates total revenues between $1.95 billion and $2.05 billion for full-year 2020 and expects to be profitable on a GAAP basis for the first time.
Tailwinds
- Total Revenues are expected to be between $1.95 billion and $2.05 billion.
- Vimizim Net Product Revenues are projected to be between $560 million and $610 million.
- Naglazyme Net Product Revenues are expected to be between $380 million and $420 million.
- Palynziq Net Product Revenues are guided to be between $180 million and $210 million.
- Brineura Net Product Revenues are projected to be between $85 million and $115 million.
Headwinds
- Cost of Sales is expected to be 20% to 21% of Total Revenues.
- Research and Development Expense is projected to be between $675 million and $725 million.
- Selling, General, and Administrative Expense is expected to be between $780 million and $830 million.
- GAAP Net Income is guided to be between $20 million and $80 million.
- Non-GAAP Income is projected to be between $260 million and $310 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-0.5%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-0.6%
Avg return
30 days after
44%
30 / 68 earnings
Positive
+9.0%
Q3 2014
Best reaction
-10.7%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.4% | +0.0% | +1.2% | |
| Q4 2025 | -2.7% | -1.9% | -11.7% | |
| Q3 2025 | +1.4% | +1.7% | +5.4% | |
| Q1 2025 | -1.3% | -5.4% | -7.4% | |
| Q4 2024 | +4.8% | +8.5% | +8.6% | |
| Q3 2024 | -4.9% | -5.0% | -6.7% | |
| Q2 2024 | +3.2% | +5.3% | +6.7% | |
| Q1 2024 | -10.7% | -10.8% | -18.0% | |
| Q4 2023 | +3.0% | +2.4% | -3.9% | |
| Q3 2023 | -2.2% | -6.4% | +13.5% | |
| Q2 2023 | +1.6% | +1.1% | +7.1% | |
| Q1 2023 | -3.3% | +1.5% | -7.4% | |
| Q4 2022 | -2.4% | -0.9% | -7.7% | |
| Q3 2022 | -6.3% | -5.3% | +6.0% | |
| Q2 2022 | +7.3% | +10.4% | +3.4% | |
| Q1 2022 | +4.2% | +5.1% | +2.1% | |
| Q4 2021 | -9.4% | -8.5% | -7.4% | |
| Q3 2021 | +6.5% | +11.8% | +19.3% | |
| Q2 2021 | +0.2% | -1.2% | +6.6% | |
| Q1 2021 | -3.2% | -2.6% | -3.9% | |
| Q4 2020 | -7.1% | -6.5% | -9.4% | |
| Q3 2020 | +0.5% | -0.2% | +4.2% | |
| Q2 2020 | -1.8% | -2.8% | -37.9% | |
| Q1 2020 | -2.6% | -4.4% | +12.8% | |
| Q4 2019 | -1.3% | +3.7% | -12.6% | |
| Q3 2019 | +2.5% | +6.5% | +14.8% | |
| Q2 2019 | -1.9% | -4.2% | -5.4% | |
| Q1 2019 | -0.5% | +0.0% | +4.1% | |
| Q4 2018 | -3.1% | +1.7% | -2.9% | |
| Q3 2018 | +4.9% | -0.8% | +1.0% | |
| Q2 2018 | -1.5% | +4.7% | -1.0% | |
| Q1 2018 | +1.7% | +2.9% | +14.0% | |
| Q4 2017 | -1.4% | -1.4% | -6.4% | |
| Q3 2017 | -1.9% | -3.2% | -2.5% | |
| Q2 2017 | +1.7% | +1.2% | +3.0% | |
| Q1 2017 | -1.8% | -5.0% | -5.5% | |
| Q4 2016 | -2.5% | +4.6% | -2.7% | |
| Q3 2016 | -0.8% | +1.2% | +8.9% | |
| Q2 2016 | -2.5% | -6.2% | -5.6% | |
| Q1 2016 | -3.5% | — | — | |
| Q4 2015 | +5.0% | — | — | |
| Q3 2015 | +2.9% | — | — | |
| Q2 2015 | -1.7% | — | — | |
| Q1 2015 | +0.6% | — | — | |
| Q4 2014 | +2.7% | — | — | |
| Q3 2014 | +9.0% | — | — | |
| Q2 2014 | +1.3% | — | — | |
| Q1 2014 | -0.9% | — | — | |
| Q4 2013 | +1.3% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q2 2013 | +1.0% | — | — | |
| Q1 2013 | +1.4% | — | — | |
| Q4 2012 | +1.7% | — | — | |
| Q3 2012 | -4.7% | — | — | |
| Q2 2012 | -5.2% | — | — | |
| Q1 2012 | -1.4% | — | — | |
| Q4 2011 | -0.0% | — | — | |
| Q3 2011 | -7.2% | — | — | |
| Q2 2011 | -6.5% | — | — | |
| Q4 2010 | +3.2% | — | — | |
| Q1 2011 | +1.8% | — | — | |
| Q4 2008 | +0.3% | — | — | |
| Q3 2010 | +4.0% | — | — | |
| Q3 2009 | +4.0% | — | — | |
| Q4 2009 | -0.6% | — | — | |
| Q2 2009 | -0.6% | — | — | |
| Q2 2010 | -0.6% | — | — | |
| Q1 2010 | -8.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro